Role of angiotensin-converting enzyme inhibitors in the coronary artery bypass patient.
Angiotensin-converting enzyme inhibitors have been shown to prolong survival and decrease infarct size in patients after acute coronary syndromes. Now there is evidence to suggest that angiotensin-converting enzyme inhibition is beneficial in coronary artery bypass patients. This review will summarize the beneficial effects of angiotensin-converting enzyme inhibition in patients with ischemic heart disease and provide evidence to show that the routine use of angiotensin-converting enzyme inhibition in coronary artery bypass patients can improve clinical outcomes.
Lazar
Harold L
HL
Department of Cardiothoracic Surgery, Boston University School of Medicine, Boston, Massachussetts, USA. harold.lazar@bmc.org
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000818:Animals; D002986:Clinical Trials as Topic; D001026:Coronary Artery Bypass; D006801:Humans; D017202:Myocardial Ischemia / Q000517:prevention & control; D011183:Postoperative Complications / Q000517:prevention & control*
D000806:Angiotensin-Converting Enzyme Inhibitors